Navigation Links
Boston Medical Center/Boston University School of Medicine researcher receives award
Date:5/7/2008

Boston, MAM. Michael Wolfe, M.D., professor of medicine and research professor of physiology and biophysics at Boston University School of Medicine and chief of the Gastroenterology Section at Boston Medical Center, was awarded an Individual Biomedical Research Award by The Hartwell Foundation. Wolfe, considered a premier authority on the biology of GI regulatory peptides, will receive $300,000 direct cost over three years as a Hartwell Investigator for his project, Peptide Replacement Therapy Using Transgenic Stem Cells Delivered to the Small Intestinal Mucosa.

Wolfe and his colleagues are developing a technique to redress hormone and enzyme deficiencies that cause diseases such as type 1 diabetes. The technique relies on engineering stem cells that produce the missing peptides and implanting them in the small intestine.

Because of their molecular size and susceptibility to degradation by stomach acid and digestive enzymes, insulin and other hormones must currently be administered by injection. The discomfort and inconvenience associated with injections often diminish patient compliance, particularly in children, which increases the risk of long-term complications. This concern is of particular importance for patients with type 1 diabetes, who often require multiple daily insulin injections to maintain stable blood sugar. Type I diabetes is one of the most common severe chronic diseases in children (1/300 in the US) and a major cause of end-stage renal disease, blindness, cardiovascular disease and premature death in the general population.

In a manuscript published in Science in 2000, Wolfe and his collaborators reported that intestinal K-cells of transgenic mice, which normally manufacture a hormone called GIP, could be engineered to express insulin and maintain normal blood glucose levels, even after pancreatic insulin-producing (islet-beta) cells were destroyed. Employing the same genetic approach, Wolfe plans to transform stem cells that, like pancreatic islet-beta cells, will produce insulin in response to food ingestion. Using endoscopy, he plans to introduce transformed cells into the intestinal lining, where they will be programmed to become K-cells and produce insulin as well as GIP. The relocation of insulin production to the upper small intestine will hide it from the autoimmune response that destroys beta-cells in type 1 diabetes. Moreover, because K- and beta-cells are functionally similar, the K-cell appears to represent the ideal candidate for hosting the foreign insulin gene.

Wolfe is recognized as one of the worlds leading authorities on GIP, and he initially cloned the GIP cDNA and ascertained its central role as principal mediator of the enteroinsular axis. This axis functions as the hormonal connection between the intestine and pancreas following the ingestion of food. He established GIP as the likely mediator of the glycemic index and has theorized that low carbohydrate diets and gastric bypass surgery mediate their beneficial effects in part by suppressing GIP expression. He proved its importance in obesity by demonstrating functional receptors on adipocytes and by showing that GIP, like insulin, suppresses the breakdown of fat, which in essence results in an increase in fat storage.

Boston University is delighted to have been invited by The Hartwell Foundation to participate in this years competition and is deeply proud of Dr. Wolfes selection for this exceptionally competitive Individual Biomedical Research Award, said Karen Antman, MD, dean of Boston University School of Medicine and provost of Boston University Medical Campus. The award provides strategic funding for remarkably original research that combines genetic engineering, stem cell therapeutics, and gastroenterology, with exciting potential clinical implications. Private funding is vital to advancing such high-risk, high-gain work, and we are very grateful to The Hartwell Foundation for playing that role at BU.

Wolfe is highly regarded for his ability to translate his own research and others observations into the clinical arena. He has been funded nearly continuously by the National Institutes of Health since the early 1980s and is one of only a very few American academicians with an invention that culminated with a drug currently on the market (Pepcid Complete).

The Hartwell Foundation is honored to provide financial support to Dr. Wolfe, said Foundation President Frederick Dombrose, Ph.D. Participating institutions nominated exceptional individuals, making this years competition for Investigator awards very tough.


'/>"/>

Contact: Michelle Roberts
michelle.roberts@bmc.org
617-638-8491
Boston University
Source:Eurekalert

Related medicine news :

1. Boston Micromachines Multi-DM Named One of the Years Most Innovative Products
2. Boston University School of Medicine researcher recipient of Memory Ride Grant
3. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
4. AAHFNs 2008 Annual Meeting in Boston Will Be Raising the Bar in Heart Failure Care
5. Families Invited to Celebrate Shire Day at Boston Childrens Museum
6. Boston Scientific Announces New Initiatives to Increase Shareholder Value
7. Boston Scientific Announces Additions to Clinical Sciences Organization
8. Boston University School of Medicine physician receives award from AATOD
9. Boston Scientific Announces Verdict in Cordis Litigation
10. Boston Scientific Announces Sale of Cardiac Surgery and Vascular Surgery Businesses
11. Boston Scientific and GE Healthcare Announce their First Patient Data Link to Electronic Medical Record
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... ... 29, 2017 , ... Saturday, April 29, marks World Veterinary ... have on animal health and welfare as well as on public health. The ... a theme each year and this year have selected “Antimicrobial Resistance—From Awareness to ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... It's not ... are a number of illnesses that are unclear as to whether or not they ... heads. Bronchitis is one of these illnesses. So, FindaTopDoc took a look into the ...
(Date:4/28/2017)... ... ... much more than energy – it also has mental and physical benefits. According to the ... which can increase the risk of having a car accident. , This week is ... help you sleep better and feel better:, , Turn off all ...
(Date:4/28/2017)... VA (PRWEB) , ... April 28, 2017 , ... The ... volunteer board members and officers for 2017-2018. The annual board election process has been ... on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, ...
(Date:4/28/2017)... Md. (PRWEB) , ... April 28, 2017 , ... ... Association of America (UCAOA) and College of Urgent Care Medicine will host industry ... workshops, sessions and speakers will help those in the industry adapt to the ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 ... an immune response in pets such as canine, ... are of various types such as Attenuated Live ... Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated live ... virus or bacteria, which have been weakend under ...
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... 1 fiscal 2017 earnings per share (EPS) guidance ... 2019.  This is in conjunction with this morning,s announcement ... Vein Thrombosis and Nutritional Insufficiency businesses. Cardinal ... continuing operations will be at the bottom of its ...
(Date:4/18/2017)... -- Astute Medical, Inc., developer of biomarkers for better healthcare, ... the 2017 National Kidney Foundation (NKF) Spring Clinical ... 22. Physicians will present data on two biomarkers, ... acute kidney injury (AKI) during the management of patients ... Elevated levels of TIMP-2 and IGFBP-7 have been shown ...
Breaking Medicine Technology: